Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEO21-RS palbociclib neoadjuvant study in ER-positive intermediate recurrence score breast cancer
2018-000157-41Phase 2Unknown
- Sponsor
- University of Liverpool
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of palbociclib in breast cancer and estrogen receptor-positive breast cancer (2 arms), sponsored by University of Liverpool. Primary endpoint: Change in Ki67 proliferation index. Status: unknown.
02
Drugs
palbociclib
03
Conditions
breast cancerestrogen receptor-positive breast cancer
Beyond the preview
Go deeper on 2018-000157-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000157-41.